Next Article in Journal
The Role of Microfluidics for Organ on Chip Simulations
Next Article in Special Issue
Human Cell Line-Derived Monoclonal IgA Antibodies for Cancer Immunotherapy
Previous Article in Journal
Bio-Inspired Multi-Functional Drug Transport Design Concept and Simulations
Previous Article in Special Issue
Use of Recombinant Mucin Glycoprotein to Assess the Interaction of the Gastric Pathogen Helicobacter pylori with the Secreted Human Mucin MUC5AC
Article Menu

Export Article

Open AccessArticle
Bioengineering 2017, 4(2), 38; doi:10.3390/bioengineering4020038

Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans

1
Laboratory of Biochemistry, Department of Life Sciences and Technology, Beuth University of Applied Sciences Berlin, Seestrasse 64, 13347 Berlin, Germany
2
Department of Life Science Engineering, HTW Berlin University of Applied Sciences, Wilhelminenhofstraße 75a, 12459 Berlin, Germany
3
Molecular Biotechnology and Functional Genomics, Technical University of Applied Sciences Wildau, Hochschulring 1, 15745 Wildau, Germany
4
Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité Medical University Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
5
ProBioGen AG, Goethestrasse 54, 13086 Berlin, Germany
*
Author to whom correspondence should be addressed.
Academic Editor: Anthony Guiseppi-Elie
Received: 31 March 2017 / Revised: 22 April 2017 / Accepted: 24 April 2017 / Published: 28 April 2017
(This article belongs to the Special Issue Recombinant Glycoproteins)
View Full-Text   |   Download PDF [2662 KB, uploaded 28 April 2017]   |  

Abstract

Xylose is a general component of O-glycans in mammals. Core-xylosylation of N-glycans is only found in plants and helminth. Consequently, xylosylated N-glycans cause immunological response in humans. We have used the F-protein of the human respiratory syncytial virus (RSV), one of the main causes of respiratory tract infection in infants and elderly, as a model protein for vaccination. The RSV-F protein was expressed in CHO-DG44 cells, which were further modified by co-expression of β1,2-xylosyltransferase from Nicotiana tabacum. Xylosylation of RSV-F N-glycans was shown by monosaccharide analysis and MALDI-TOF mass spectrometry. In immunogenic studies with a human artificial lymph node model, the engineered RSV-F protein revealed improved vaccination efficacy. View Full-Text
Keywords: CHO; glycoengineering; respiratory syncytial virus; vaccine; xylose CHO; glycoengineering; respiratory syncytial virus; vaccine; xylose
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Sandig, G.; von Horsten, H.H.; Radke, L.; Blanchard, V.; Frohme, M.; Giese, C.; Sandig, V.; Hinderlich, S. Engineering of CHO Cells for the Production of Recombinant Glycoprotein Vaccines with Xylosylated N-glycans. Bioengineering 2017, 4, 38.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Bioengineering EISSN 2306-5354 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top